Drug candidate, CQ-001, supported by (cannabidiol “CBD” + IP formula) – molecules bond and synergistically attach to PPAR receptors allowing CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) with amplified effects and efficacy.
CBD by itself did not do this in the pre-clinical trials.

Pre-clinical trial results – published in peer-reviewed European Journal of Neuroscience. Oct. 2020.

Drug candidate, CQ-002, supported by (cannabinoid “THC” + IP formula) – is a safer alternative to all other THC products. Pre-clinical trials demonstrated reversal of depression-like and schizophrenia related symptoms, complete blockage of memory impairment, hyperactive activity, and gene vulnerability.

Pre-clinical trial results – published in peer-reviewed European Journal of Neuroscience Oct. 2020 & International Journal of Molecular Sciences July 2021.

The Company intends to incorporate Artificial Intelligence (AI) to help diagnose and evaluate mental health at the beginning and through the medication period. By including advanced machine learning algorithms, novel formulation methods, and well-established industry approaches, we are driving the evolution of the mental health industry to improve the lives of millions globally.

CanaQuest has research and clinical trial collaborations with multiple Canadian universities and Institutions and has identified the regulatory pathways for CQ-001 to obtain Rx Drug Identification Numbers (DINs) in the USA and Canada for Epilepsy rare neurological conditions, projected ∼ 3 years.

Western University
Pre-clinical trials completed for CQ-001 and CQ-002
Dr. Laviolette is a scientific veteran with 20 years of research experience in the field of mental health and cannabinoids and he oversees a dedicated team of 13 scientists, with a focus on neuropsychiatric disorders like anxiety, depression, post-traumatic stress disorder (PTSD), and Addiction.

University of Montreal
Q2 2022 – initiating pre-approved clinical trial (Phase II, randomized, triple-blind crossover feasibility study) for efficacy and dosage of our cannabinoid based formulated drug-candidates, CQ-001 and CQ-002, for the treatment of Cannabis Use Disorder “CUD”.

McMaster University
Q3 2022 – initiating clinical trial (Phase II, double-blind feasibility trial, 30 patients) to further refine efficacy and dosage of CQ-001 for humans.

Ontario Brain Institute
Q2 2022 – EpLink, the Epilepsy Research Program funded by the Ontario Brain Institute, is conducting a study using rodent models to establish dosing requirements for CQ-001. These results will set the stage for clinical trials to treat refractory epileptic syndromes (high efficacy, less dosage, reduced negative side effects).

Q4 2022 – study results will define dosage of CQ-001 for clinical trial (Phase II/III, double-blind trial, 60 patients) and will facilitate a submission to Health Canada and subsequently, the US-FDA for a new drug.

Hydrx Farms
Q3 2022 – our Contract Manufacturer, GMP and clinical trial compliance, is completing the SOPs for the Clinical Trial Application process required for the approved and funded clinical trial at the University of Montreal (Cannabis Use Disorder – efficacy, dosage, and safety, 24 patients), for evaluating CanaQuest’s CQ-001 and CQ-002 drug candidates.

Mentanine - COA (Original) - Datasheet